Gevo, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Gevo, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $711.0K | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $5.54M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $24.49M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $32.86M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $27.54M | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | $27.21M | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $30.14M | Mar 28, 2018 |
| FY2016 | Dec 31, 2014 | $28.27M | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $8.22M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $24.39M | Mar 30, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.58M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $16.92M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $17.20M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.18M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $533.0K | Mar 9, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | ($11.45M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | ($9.47M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | ($12.25M) | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | ($8.71M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($10.63M) | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | ($9.80M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | ($8.63M) | Mar 28, 2018 |
| FY2016 | Dec 31, 2014 | ($7.32M) | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | ($9.69M) | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | ($8.03M) | Mar 30, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.84M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($78.64M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($66.22M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($98.01M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($59.20M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($40.19M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | ($28.66M) | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | ($27.98M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($24.63M) | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | ($37.23M) | Mar 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.21M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($90.82M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($81.84M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($102.69M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($60.27M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($26.96M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | ($26.36M) | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | ($22.20M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($23.28M) | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | ($23.99M) | Mar 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.55M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $5.58M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $6.64M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $7.43M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $6.78M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $3.51M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $3.87M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $5.37M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $5.18M | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | $5.22M | Mar 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $25.49M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $11.19M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $9.82M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $8.12M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $7.47M | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | $8.97M | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $16.69M | Mar 28, 2018 |
| FY2016 | Dec 31, 2014 | $18.34M | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $25.55M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $43.98M | Mar 30, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.40M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($57.38M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($53.72M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($44.31M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($48.27M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($19.34M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | ($20.84M) | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | ($15.85M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($20.63M) | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | ($20.52M) | Mar 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.11M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $51.09M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $54.46M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $84.08M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $56.77M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.22M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $6.50M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $2.23M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.91M | Mar 28, 2019 |
| FY2018 | Dec 31, 2016 | $5.94M | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $718.93M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $583.94M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $650.32M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $700.75M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $645.38M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $152.10M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $93.36M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $107.04M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $88.85M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $112.32M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $247.76M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $94.45M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $92.93M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $95.27M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $98.13M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $5.72M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $20.86M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $18.25M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $25.32M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $43.06M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $466.34M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $489.49M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $557.39M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $605.48M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $547.26M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $146.38M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $72.50M | Feb 24, 2022 |
| FY2021 | Dec 31, 2018 | $88.79M | Feb 24, 2022 |
| FY2019 | Dec 31, 2017 | $63.53M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | $69.26M | Mar 28, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.56M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.74M | Mar 5, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($834.15M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($800.24M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($721.60M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($655.38M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($557.38M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($498.17M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($457.99M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($429.33M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($401.35M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($376.72M) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.16M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $189.39M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $298.35M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $237.13M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $40.83M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $78.34M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $16.30M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $33.73M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $11.55M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $27.89M | Mar 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.75M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $67.13M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $68.12M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $67.54M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $66.96M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.25M | Feb 24, 2022 |
| FY2019 | Dec 31, 2019 | $749.0K | Mar 17, 2020 |
| FY2016 | Dec 31, 2016 | $35.68M | Mar 31, 2017 |
| FY2015 | Dec 31, 2015 | $49.01M | Mar 30, 2016 |
| FY2014 | Dec 31, 2014 | $53.83M | Mar 30, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 242.46M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 239.18M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 240.50M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 237.17M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 201.99M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 128.14M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 14.08M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 8.64M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 1.09M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 7.07M | Mar 28, 2018 |